Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3314814 in Mild Alzheimer's Disease
CTR20170591Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lanabecestat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Feb 2018; status: active.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20170591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170591.